Hale David F - Apr 7, 2022 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
Director
Signature
/s/ Gerald T. Proehl, Attorney-in-Fact
Stock symbol
DRMA
Transactions as of
Apr 7, 2022
Transactions value $
$0
Form type
4
Date filed
4/8/2022, 07:12 PM
Previous filing
Jan 5, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRMA Common Stock Award $0 +15.5K +422.8% $0.00 19.1K Apr 7, 2022 Direct F1
holding DRMA Common Stock 12.2K Apr 7, 2022 By Hale Trading Company L.P. F2
holding DRMA Common Stock 255K Apr 7, 2022 By Hale BioVentures LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 7, 2022, the Reporting Person was granted 15,466 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
F2 Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.